Clinical Trials Browser

Phase 1/2 × INDUSTRY × durvalumab × Clear all

NCT04068610 2026-05-15

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Phase 1/2 Active not recruiting

61 enrolled 35 charts

Gastrointestinal

Colonic Neoplasms

NCT03742102 2026-04-24

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03837899 2026-04-21

Durvalumab and Tremelimumab for Pediatric Malignancies

Phase 1/2 Active not recruiting

50 enrolled 59 charts

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT02734004 2026-04-20

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT06780137 2026-04-20

MK-6070-002

Phase 1/2 Recruiting

Small Cell Lung Carcinoma

NCT02499328 2026-02-11

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Phase 1/2 Completed

340 enrolled 53 charts

Head & NeckOther solid neoplasm

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT06939036 2026-02-05

SANTANA-225

Phase 1/2 Terminated

Carcinoma, Merkel Cell

NCT07174583 2026-01-23

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Phase 1/2 Recruiting

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT04538742 2025-12-08

DB-07

Phase 1/2 Active not recruiting

Brain Neoplasms, Breast Neoplasms

NCT02671435 2025-07-22

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Phase 1/2 Active not recruiting

383 enrolled 48 charts

Neoplasm Metastasis

NCT03323398 2024-07-31

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Phase 1/2 Terminated

79 enrolled 18 charts

GynecologicLymphoid

Lymphoma, Ovarian Neoplasms, Recurrence

NCT03310619 2024-04-04

PLATFORM

Phase 1/2 Completed

62 enrolled 41 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02733042 2023-11-18

FUSION NHL 001

Phase 1/2 Completed

106 enrolled 48 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06111326 2023-11-01

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

Phase 1/2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT02685826 2023-10-06

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

Phase 1/2 Completed

56 enrolled 38 charts

Multiple Myeloma

NCT03611556 2023-10-03

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Phase 1/2 Completed

213 enrolled 42 charts

Gastrointestinal

Carcinoma, Pancreatic Neoplasms

NCT03970616 2023-07-12

DEDUCTIVE

Phase 1/2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

NCT02291055 2023-03-20

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Phase 1/2 Terminated

75 enrolled 23 charts

GynecologicHead & Neck

Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms

NCT03162224 2022-08-25

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Phase 1/2 Completed

35 enrolled 25 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT02318277 2022-01-13

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Phase 1/2 Completed

176 enrolled 25 charts

Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

NCT02118337 2021-06-01

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

Phase 1/2 Completed

97 enrolled 40 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01693562 2021-05-13

A Phase 1/2 Study to Evaluate MEDI4736

Phase 1/2 Completed

1,022 enrolled 42 charts

Other solid neoplasm

Advanced Solid Tumors

NCT02805660 2021-04-06

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Phase 1/2 Terminated

83 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Phase 1/2 Terminated

Solid Cancer

NCT02401048 2019-06-27

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Phase 1/2 Completed

61 enrolled 24 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02403271 2019-01-03

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Phase 1/2 Completed

124 enrolled 17 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms

NCT02205333 2017-06-28

MEDI6469

Phase 1/2 Terminated

48 enrolled 28 charts

Lymphoma, Large B-Cell, Diffuse